STOCK TITAN

AYTU BioPharma enters merger agreement with Rosemont

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SC TO-C

Rhea-AI Filing Summary

AYTU BioPharma, Inc. is party to an Agreement and Plan of Merger dated November 16, 2026, with Rosemont Pharmaceuticals Holdings, Inc. and RoseApollo Merger Sub, Inc., the parent’s wholly owned subsidiary. Rosemont plans to cause Merger Sub to commence a tender offer for all outstanding AYTU common shares; the offer has not yet commenced. When it begins, the offerors plan to file tender offer materials on Schedule TO, and AYTU plans to file a Schedule 14D-9 recommendation statement.

tender offer regulatory
"commence a tender offer for all of the outstanding shares"
A tender offer is a proposal made by a person or company to buy shares from existing shareholders at a set price, usually higher than the current market value, within a specific time frame. It matters to investors because it can lead to a change in ownership or control of a company, and shareholders must decide whether to sell their shares at the offered price.
Agreement and Plan of Merger regulatory
"pursuant to the Agreement and Plan of Merger"
An Agreement and Plan of Merger is a formal document where two companies agree to combine into one, outlining how the process will happen. It’s like a step-by-step plan for merging, and it matters because it shows both sides have agreed on the details before the official transition takes place.
Solicitation/Recommendation Statement regulatory
"the Company will file a Solicitation/Recommendation Statement on Schedule 14D-9"
A solicitation/recommendation statement is a public message from a company, board member, shareholder or advisor that asks investors to take a specific action—such as voting a proxy, tendering shares, or accepting or rejecting an offer—and explains which choice the issuer recommends. It matters to investors because these statements aim to shape outcomes that affect ownership, control or value, and they are often subject to disclosure rules so readers can judge the source’s motives and reliability; think of it like a persuasive letter that also must show who wrote it and why.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Has the AYTU tender offer started?

No. RoseApollo Merger Sub’s planned tender offer for all outstanding AYTU common shares has not yet commenced.

What documents will be filed when the AYTU tender offer begins?

Rosemont Pharmaceuticals Holdings and RoseApollo Merger Sub plan to file tender offer materials on Schedule TO, while AYTU plans to file a Solicitation/Recommendation Statement on Schedule 14D-9.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

 


 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 

 

SCHEDULE TO

 

Tender Offer Statement under Section 14(d)(1) or 13(e)(1)

of the Securities Exchange Act of 1934 

 

AYTU BIOPHARMA, INC.

(Name of Subject Company (issuer))

 

ROSEAPOLLO MERGER SUB, Inc.

(Offeror)

 

A wholly-owned subsidiary of

Rosemont Pharmaceuticals Holdings, Inc.

(Parent of Offeror)

(Names of Filing Persons (identifying status as offeror, issuer or other person))

 

Common stock, $0.0001 par value per share

(Title of Class of Securities)

 

054754858

(CUSIP Number of Class of Securities)

  

Kerry Sharp

General Counsel

Rosemont Pharmaceuticals Ltd.

Rosemont House, Yorkdale Industrial Park, Braithwaite Street,

Leeds, LS11 9XE

Telephone: +44 (0)113 244 1400

(Name, address, and telephone numbers of person authorized to receive notices and communications on behalf of filing persons)

 

Copy to:

Jackie Cohen; Janet Coscino

Ropes & Gray, LLP

1211 Avenue of the Americas

New York, New York 10036 

 

xCheck the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

 

Check the appropriate boxes below to designate any transactions to which the statement relates:

 

xThird-party tender offer subject to Rule 14d-1.

¨Going-private transaction subject to Rule 13e-3.

¨Issuer tender offer subject to Rule 13e-4.

¨Amendment to Schedule 13D under Rule 13d-2.

 

Check the following box if the filing is a final amendment reporting the results of the tender offer: ¨

 

If applicable, check the appropriate box(es) below to designate the appropriate rule provision(s) relied upon:

 

¨Rule 13e-4(i) (Cross-Border Issuer Tender Offer).

¨Rule 14d-1(d) (Cross-Border Third-Party Tender Offer).

  

 

 

 

 

This Tender Offer Statement on Schedule TO relates solely to preliminary communications made before the commencement of a planned tender offer by RoseApollo Merger Sub, Inc., a Delaware corporation (“Purchaser”) and a wholly owned subsidiary of Rosemont Pharmaceuticals Holdings, Inc., a Delaware corporation (“Parent”), for all of the outstanding shares of common stock of Aytu BioPharma, Inc., a Delaware corporation (the “Company”), pursuant to the Agreement and Plan of Merger, dated as of November 16, 2026 (the “Merger Agreement”), among Parent, Purchaser and the Company.

 

In connection with the proposed acquisition of the Company, Parent will cause Purchaser to commence a tender offer for all of the outstanding shares of common stock of the Company. The tender offer for all of the outstanding shares of the Company described in this filing has not yet commenced. This filing is for informational purposes only, is not a recommendation and is neither an offer to purchase nor a solicitation of an offer to sell any securities, nor is it a substitute for the tender offer materials that Parent and Purchaser will file with the SEC upon commencement of the tender offer. A solicitation and offer to buy outstanding shares of the Company will only be made pursuant to the tender offer materials that Rosemont and its acquisition subsidiary intend to file with the SEC. At the time the tender offer is commenced, Parent and Purchaser will file tender offer materials on Schedule TO, and the Company will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC with respect to the tender offer. THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED ACQUISITION AND THE PARTIES THERETO. INVESTORS AND STOCKHOLDERS OF THE COMPANY ARE URGED TO READ THESE DOCUMENTS CAREFULLY WHEN THEY BECOME AVAILABLE (AND EACH AS IT MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME) BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT INVESTORS AND STOCKHOLDERS OF THE COMPANY SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR SHARES OF COMMON STOCK IN THE TENDER OFFER. The tender offer materials (including the Offer to Purchase and the related Letter of Transmittal), as well as the Solicitation/Recommendation Statement, will be made available to all stockholders of the Company at no expense to them on the SEC’s website at www.sec.gov and (once they become available) will be mailed to the stockholders of the Company free of charge. Additional copies may be obtained for free by contacting the Company, or by contacting Sodali & Co, the information agent for the Offer, toll-free at (800) 662-5200 or at AYTU.info@investor.sodali.com The information contained in, or that can be accessed through, the SEC’s website is not a part of, or incorporated by reference herein. In addition to the Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, the Company files annual, quarterly, and current reports, proxy statements and other information with the SEC. You may read any reports, statements or other information filed by the Company with the SEC for free on the SEC’s website at www.sec.gov.

 

Cautionary Statement Regarding Forward-Looking Statements

 

This filing includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (“Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (“Exchange Act”). All statements other than statements of historical facts contained in this press release are forward-looking statements. Forward-looking statements are generally written in the future tense and/or are preceded by words such as “may,” “will,” “should,” “forecast,” “could,” “expect,” “suggest,” “believe,” “estimate,” “continue,” “anticipate,” “intend,” “plan,” or similar words, or the negatives of such terms or other variations on such terms or comparable terminology. These statements are predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include, among others, risks associated with: uncertainties as to the timing of the tender offer and the merger; uncertainties as to how many stockholders of the Company will tender their shares in the tender offer; the possibility that the conditions to the tender offer and the merger may not be satisfied or waived; the occurrence of any event that could give rise to the termination of the merger agreement; the effects of the transaction on relationships with employees, customers, suppliers and other business partners; potential stockholder litigation or regulatory action relating to the transaction; the Company’s overall financial and operational performance, potential adverse changes to the Company’s financial position or its business, the results of operations, strategy and plans, changes in capital markets and the ability of the Company to finance operations in the manner expected, risks relating to gaining market acceptance of its products, its partners performing their required activities, its anticipated future cash position, regulatory and compliance challenges and future events under current and potential future collaborations. Readers should refer to the risks described in “Risk Factors” in Part I, Item 1A of the Company’s most recent Annual Report on Form 10-K and in the other reports and documents it files with the United States Securities and Exchange Commission, as well as the tender offer documents to be filed by Rosemont and the Schedule 14D-9 to be filed by the Company.

 

Item 12. Exhibits

 

     
Exhibit No.   Description
   
Exhibit 99.1   Press Release issued on November 16, 2026

 

 

 

Keep reading